Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Finding the Universe of Workmanship: Individual Encounters in Imagination - 2Santa's sleigh or the International Space Station? How to spot a bright Christmas flyby Dec. 24 and 25
- 3Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- 4Colleges say foreign students feel 'unwelcome' in the U.S. amid big drop in international enrollment, new survey finds
- 5Five held on suspicion of planning attack on German Christmas market
- Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women
- Step by step instructions to Pick an Incineration Urn: Variables to Consider
- The Way to Recuperation: Defeating Dependence
- 6 Famous Urban communities for Shopping on the planet
- The Best Games Crossroads in History
- Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- Holocaust survivor, descendants urge High Court to allow Gaza children medical access
- Artemis II crew take new photo of far side of the moon
- A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
